The endogenous opioid peptide, beta-endorphin, is present in the brain in neurons of the hypothalamic arcuate nucleus.
The aim of the present application is to test whether a subset of endorphinergic neurons that project from the arcuate nucleus to the dorsal medullary nucleus of the solitary tract (NTS) is involved in cardiovascular regulation. Specifically, the first hypothesis to be tested is that these neurons may be activated by antihypertensive drugs acting at alpha2-adrenergic receptors in the arcuate nucleus, and that the resulting release of beta- endorphin and subsequent activation of opiate receptors in the NTS contributes to the hypotensive, bradycardic and baroreflex facilitatory effects of these drugs (e.g. alpha-methyldopa, clonidine). The second hypothesis to be tested is that the same endorphinergic neurons may be also involved in mediating the hypotension elicited by endotoxin treatment, as suggested by remarkable similarities between the opioid component in the hypotension induced by centrally acting alpha2-receptor agonists and in the hypotension associated with various forms of shock, including endotoxic shock. The experiments proposed will combine neuropharmacological and molecular biological approaches for testing these hypotheses in rats. In the first type of experiments we will examine whether alpha2-receptor agonists microinjected into the arcuate nucleus cause hypotension and bradycardia inhibited by alpha2-receptor antagonists injected into the same site. Furthermore, will test whether these effects, as well as the hypotension elicited by endotoxin treatment, can be inhibited by opiate antagonists or beta-endorphin antiserum microinjected into the ipsilateral NTS, or by surgical deafferentation of the NTS. The second type of experiment will explore the effects of chronic treatment of rats with alpha2-receptor agonists with and without antagonists, as well as chronic treatment with endotoxin, on the gene expression of the precursor of beta-endorphin, proopiomelanocortin (POMC), in the arcuate nucleus and its subregions. The level of neuropeptide mRNA in a neuron is considered a good indicator of the physiological activity of that neuron. The proposed experiments could provide new insight into mechanisms of antihypertensive drug action and into the mechanism of endogenous opioid involvement in the cardiovascular changes associated with certain forms of shock.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
1R01HL049938-01A1
Application #
2225990
Study Section
Experimental Cardiovascular Sciences Study Section (ECS)
Project Start
1994-01-14
Project End
1996-11-30
Budget Start
1994-01-14
Budget End
1994-11-30
Support Year
1
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Virginia Commonwealth University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
City
Richmond
State
VA
Country
United States
Zip Code
23298
Wagner, J A; Jarai, Z; Batkai, S et al. (2001) Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors. Eur J Pharmacol 423:203-10
Kunos, G; Jarai, Z; Varga, K et al. (2000) Cardiovascular effects of endocannabinoids--the plot thickens. Prostaglandins Other Lipid Mediat 61:71-84
Kunos, G; Jarai, Z; Batkai, S et al. (2000) Endocannabinoids as cardiovascular modulators. Chem Phys Lipids 108:159-68
Wagner, J A; Varga, K; Jarai, Z et al. (1999) Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension 33:429-34
Auer, K L; Spector, M S; Tombes, R M et al. (1998) Alpha-adrenergic inhibition of proliferation in HepG2 cells stably transfected with the alpha1B-adrenergic receptor through a p42MAPkinase/p21Cip1/WAF1-dependent pathway. FEBS Lett 436:131-8
Lake, K D; Martin, B R; Kunos, G et al. (1997) Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats. Hypertension 29:1204-10
Lake, K D; Compton, D R; Varga, K et al. (1997) Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors. J Pharmacol Exp Ther 281:1030-7
Li, S J; Varga, K; Archer, P et al. (1996) Melanocortin antagonists define two distinct pathways of cardiovascular control by alpha- and gamma-melanocyte-stimulating hormones. J Neurosci 16:5182-8
Ishac, E J; Jiang, L; Lake, K D et al. (1996) Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol 118:2023-8
Varga, K; Lake, K D; Huangfu, D et al. (1996) Mechanism of the hypotensive action of anandamide in anesthetized rats. Hypertension 28:682-6

Showing the most recent 10 out of 14 publications